Commercial Space Company Risk / Opportunity Ranking

Thesis: Recent very large funding, high stated valuation, and evidence of expanding sovereign SAR demand support a durable multi-quarter scaling thesis.

Why now: On June 9, 2026 ICEYE disclosed a €450 million primary Series F at valuation above €10 billion, with total round size above €1 billion including secondary, and later June context also referenced a €300 million revolving credit facility and additional sovereign satellite demand; those are recent business-state signals for a 1 year+ horizon.

Caveats: Some support is supporting article context rather than company-specific positive evidence. Several supporting demand/customer references are undated, so recency is uncertain for those claims.

Thesis: SpaceX has the strongest evidence-set-backed long-horizon opportunity because it secured multiple large, recent government awards that deepen its role as a core military and civil space infrastructure provider, with contract scope spanning surveillance, communications backbone, and additional NASA crew missions.

Why now: The timing is supported by late-May 2026 contract awards: a $2.29 billion Space Force data-network award dated May 26, 2026 and a $4.16 billion Space Force SB-AMTI award dated May 29, 2026/May 30, 2026, plus NASA's plan dated May 24, 2026 to add missions to SpaceX's commercial crew contract, all of which indicate durable backlog expansion and franchise entrenchment over a 1 year+ horizon.

Caveats: The reviewed sources' available source fields contain no direct positive or negative events for SpaceX; opportunity is inferred from high-materiality neutral facts and article summaries. Ticker mapping is noisy in the reviewed sources: SpaceX is shown with ticker TSLA, which should not be treated as validated public-company identity here.

Thesis: Apex has the strongest opportunity case in this screen because multiple dated June 2026 sources say it raised over $200 million at a $2.3 billion valuation specifically to scale high-rate satellite bus production for proliferated constellations, and a separate dated June 2026 article says Northrop partnered with Apex on space-based interceptors for Golden Dome. Together, these indicate fresh capital, scaling intent, and positioning with government/defense demand vectors over a 1 year+ horizon.

Why now: Why now is strong because the key financing evidence is dated June 5, 2026 and the Northrop partnership article is dated June 1, 2026, making both recent within the 90-day recent evidence window and relevant to a 1 year+ scaling thesis. The June 5 financing event is later than the April 16 capacity/context article and therefore better reflects current business state.

Caveats: Most available evidence is neutral fact or supporting article context, not explicit positive events. Same-day repeated articles around the fundraise are not independent proof beyond corroboration. Some context sources are company-issued or article-level summaries, which are weaker than direct events.

Thesis: AST SpaceMobile has strong long-horizon opportunity because it achieved a critical regulatory milestone for a 248-satellite direct-to-device constellation and continues to show ecosystem buildout through operator partnerships and stated constellation scale targets.

Why now: The key timing event is the FCC authorization dated April 21, 2026/April 22, 2026 granting authority for up to 248 satellites and direct-to-device service, a milestone that can unlock U.S. commercial and government use cases over a 1 year+ horizon. Later-dated company-site context on June 23, 2026 also says AST has nearly 60 operator partners and targets direct broadband to standard smartphones.

Caveats: Much of the evidence is company, press-release, or article-context based rather than independent hard performance metrics. The reviewed sources cites a target of 45 to 60 BlueBird satellites by end-2026 in article summary context, but this is not available as a direct structured fact here.

Thesis: BlackSky has the strongest recent opportunity evidence in the screen: a multi-year sole-source $99 million U.S. government IDIQ tied to next-generation Earth observation and space domain awareness development, plus a separate $25 million multi-year assured contract with a major international defense customer. Together these indicate current government demand, product validation, and longer-horizon backlog/ARR support.

Why now: The why-now is supported by two dated recent wins inside the recent evidence window: on March 31, 2026 BlackSky said it received a multi-year sole-source $99 million U.S. government IDIQ and initial $2 million funding for advanced large-aperture payload design; on April 22, 2026 it announced a competitive $25 million multi-year assured contract with a major international defense customer and said it had four Gen-3 satellites on orbit and was rapidly deploying Gen-3 capacity while driving up backlog and annual recurring revenue.

Caveats: The $99 million figure is an IDIQ ceiling, not fully funded revenue at announcement; only an initial $2 million was specifically disclosed. Some corroboration repeats the same underlying announcement and should not be treated as independent evidence

Thesis: Boeing has the strongest opportunity evidence in this screen because the reviewed sources includes recent company-linked fact evidence that it won a $2 billion U.S. Space Force contract to build two next-generation MUOS communications satellites. The award covers design, development, production, testing, and on-orbit support for a critical military SATCOM network, with launches no earlier than 2031 and 2032 and constellation support through 2035. That is a material, durable space/defense win aligned with the 1 year+ horizon

Why now: Why now is strong because the contract was reported on June 23-25, 2026, making it recent within the 90-day recent evidence window, and it represents a fresh, material U.S. defense-space award with multiyear strategic relevance

Caveats: Some corroborating rows are supporting article context and should not be overcounted as independent confirmation. Program financial benefits may phase in over a long cycle given first delivery timing in 2031.

Thesis: Capella Space has the strongest opportunity profile in this screen because the reviewed sources includes a dated, company-specific contract fact showing it won a roughly $49 million SDA contract to build two satellites for a military communications demonstration, adding to evidence that it operates advanced SAR satellite capabilities and serves government and strategic customers.

Why now: The April 8, 2026 SDA award is recent within the recent evidence window and is directly relevant to a 1 year+ horizon because it funds spacecraft design and development for a government demonstration program. Later context articles in April-June 2026 continue to depict Capella as an operating SAR platform with defense exposure.

Caveats: The positive contract evidence is classified as a neutral supporting fact in the reviewed sources, so direction is inferred from the business substance rather than explicit positive polarity labeling. Several contextual articles mention a planned acquisition or subsidiary status, but time-sensitive ownership/public-status interpretations should be treated cautiously because not all such references are direct, dated transaction-closing evidence. For example, and

Thesis: Impulse Space has the strongest opportunity setup in this screen based on recent, company-linked financing evidence that it raised $500 million in Series D funding to scale production of orbital transfer vehicles, with article context also indicating expansion to support growing commercial and government demand. For a 1 year+ horizon, that capital base can support production scale-up and program execution.

Why now: The catalyst is recent and dated: on June 2, 2026/June 3, 2026, Impulse Space disclosed a $500 million Series D and total capital raised above $1 billion, which is highly relevant for a 1 year+ scaling thesis.

Caveats: Some supportive items are supporting article context and should not be treated as independent confirmation if repeating the same financing announcement. Older commercial contract and government contract references in representative articles are outside the 90-day recent evidence window and therefore not primary recency support here.

Thesis: Katalyst Space Technologies has a strong opportunity profile because the reviewed sources show recent evidence of both mission relevance and financing: a NASA Phase III SBIR contract to develop a rescue concept for the Neil Gehrels Swift Observatory and a later June 23, 2026 report that it raised $12 million to develop its NEXUS robotic spacecraft and expand satellite servicing.

Why now: Why now is strong because the latest dated evidence on June 23, 2026 adds new capital after the May 29, 2026 NASA-related mission context, supporting a 1 year+ thesis that the company is moving from concept credibility toward funded development in on-orbit servicing.

Caveats: Part of the positive case comes from company-issued materials and supporting article context rather than independent positive evidence. The May 29, 2026 article includes a dated source date but describes an announcement text beginning 'August 11, 2025'; chronology should therefore be read carefully, with the treated as the recency marker for this retrieved item. Citation

Thesis: Northrop Grumman has the strongest reviewed sources-supported opportunity profile in this screen due to multiple recent space-defense catalysts: inclusion in the April 8, 2026 Andromeda RG-XX awards, a June 1, 2026 partnership with Apex on Golden Dome space-based interceptors, and a June 22, 2026 $398M Space Force contract for the Enhanced Protected Tactical SATCOM Prototype. Together these support a durable 1 year+ defense-space demand thesis.

Why now: The setup is current and cumulative: April 8, 2026 Andromeda participation, June 1, 2026 Golden Dome interceptor partnership, and June 22, 2026 award of a $398M protected satcom contract all fall within the 90-day recent evidence window and point to sustained momentum.

Caveats: The reviewed sources does not provide direct business impact breakdowns beyond the $398M contract article. Some support is supporting article context rather than dated events.

Thesis: Observable Space has the strongest positive setup in this screen because the reviewed sources contain dated evidence that it raised a $90 million Series A and secured a $94 million U.S. Space Force optical-systems contract, supporting capital availability, customer validation, and potential multi-quarter execution runway.

Why now: The timing is favorable because on May 28, 2026 the company was reported to have both closed a $90 million Series A and announced a $94 million U.S. Space Force award, with additional follow-on reporting on June 9, 2026 indicating the contract landed just weeks after the raise, suggesting a recent step-change in funding and government traction for a 1 year+ horizon

Caveats: Positive direction is inferred from neutral facts plus article summaries; the reviewed sources does not provide explicit positive events. Same-article repeated rows are not independent confirmation. Supporting web-search evidence is context and should be treated below directly cited company evidence.

Thesis: PLD Space has recent financing, strategic customer/investor validation, infrastructure investment, and a first commercial launch contract, all of which support a durable launch-scaling thesis over the next year-plus.

Why now: The reviewed sources show a sequence of material developments: €180 million Series C on March 4, 2026, €30 million EIB venture debt signed April 7, 2026 and reported May 6, 2026/04-07, first commercial contract reported May 21, 2026, and €35 million Kourou launch-complex investment on June 1, 2026 while MIURA 5 remained on track for a late-2026 first test flight. That is strong state-change evidence for a 1 year+ horizon.

Caveats: Risk evidence is partly inferred from dependency on future launch milestones rather than a disclosed adverse event. Most support is supporting article context, though the chronology is consistent and material.

Thesis: Quantum Space has the clearest evidence-backed opportunity profile in this screen: within the recent evidence window it announced a SPAC merger expected to bring substantial capital and public-market access, and later won a Pentagon-funded orbital refueling spacecraft contract built on its Ranger platform. Those developments support a durable 1 year+ thesis around funding access, national-security positioning, and product relevance in on-orbit logistics.

Why now: The evidence is recent and sequenced: on June 8, 2026 Quantum Space announced its planned SPAC merger and expected Nasdaq listing under QSPC

Caveats: Most available evidence is external overlay context rather than first-party positive or negative events. Same-theme repetition across June articles is not independent confirmation. Ticker QSPC is prospective after the expected SPAC close per June 8, 2026 evidence, not confirmed as already trading under that symbol

Thesis: True Anomaly has the strongest opportunity profile in this screen because the reviewed sources contain dated, company-linked evidence that it raised $650 million in Series D financing at a $2.2 billion valuation on April 28, 2026 and was selected by the U.S. Space Force for the Space-Based Interceptor program on May 4, 2026. For a 1 year+ horizon, that combination of fresh capital plus program participation supports scaling, product development, and defense-space positioning.

Why now: The recent sequence matters: on April 28, 2026, True Anomaly announced a $650 million Series D at a $2.2 billion valuation, also. Then on May 4, 2026, a dated article said the company was selected by the U.S. Space Force Space Systems Command for the Space-Based Interceptor program. That capital-plus-program sequence is directly relevant to a long-horizon growth thesis.

Caveats: Most evidence is external overlay context/facts rather than primary data source direct events. Several sources repeat the same April 28 financing story and are not independent confirmation of different events. The company-site article is undated, so recency-sensitive claims from it should be treated cautiously.

Thesis: Anduril has a credible 1 year+ opportunity setup from recent participation in major U.S. defense-space programs and fresh financing context. Recent article context says Anduril was among companies awarded Space Force Andromeda contracts for the RG-XX satellite effort on April 8, 2026, and a later article says Anduril raised a $5B Series H round published June 19, 2026, supporting capital availability for scaling in defense-space programs.

Why now: The timing is supported by recent 2026 article context around Space Force Andromeda participation and the June 19, 2026 financing context, which together suggest active momentum over the last quarter.

Caveats: Most evidence is weak context-only article evidence, not direct positive events in the available ranking rows.

Thesis: Astroscale has the clearest 1 year+ opportunity setup in this screen: within the recent evidence window article context shows recent funding support, strategic growth financing for medium-to-long-term expansion, and a shift from demos toward repeatable commercial missions, including defense-related servicing and a 2027 inspection mission pipeline.

Why now: Recency is the main reason: on June 22, 2026 SpaceNews said Astroscale was 'working to transition from technology demonstrations to a regular series of missions, bolstered by a recent capital infusion' and saw 'repeatable business opportunities' particularly among defense customers. On May 19, 2026 financing materials said the company would raise 30.6 billion yen to secure medium-to-long-term growth funding 'in anticipation of transitioning to a phase of continuous order acquisition'. On April 6, 2026 Astroscale revealed its ISSA-J1 mission scheduled for launch in 2027.

Caveats: Most within the recent evidence window evidence is supporting article context, not structured company-specific events; reviewed sources warns supporting article context is weaker than direct event/fact evidence. Same-article repeated weak-context rows are not independent confirmation. Older 2023 and 2025 articles exist in representative articles but fall outside the 90-day recent evidence window for ranking use.

Thesis: Best opportunity profile in this screen based on multiple dated article-context items showing the company remains active in in-orbit servicing/debris removal, has financing support, is ramping toward ClearSpace-1, and is expanding into defense-adjacent partnership activity. For a 1 year+ horizon, that combination supports a credible strategic growth and market-positioning thesis.

Why now: Why now is supported by recent dated context: on June 24, 2026, SpaceNews reported ClearSpace signed an MOU with Shield Space to develop sovereign space defense capabilities for the UK and allies, indicating adjacent market expansion. On May 19, 2026, the company site said it had finalized a EUR 26.7 million Series A and was ramping operations ahead of ClearSpace-1 scheduled to launch in 2026. These dated items fit a 1 year+ horizon because they point to ongoing commercialization and mission preparation.

Caveats: Most evidence is supporting article context, not direct positive events. The financing article published on May 19, 2026 references January 19, 2023 for the Series A round, so funding recency versus page recency should not be conflated.

Thesis: Cowboy Space has the strongest positive evidence in this screen: a large Series B financing at a substantial valuation, explicit plans to build vertically integrated rockets plus orbital data-center infrastructure, and stated hiring/buildout activity. That combination supports a durable 1 year+ strategic opportunity thesis.

Why now: Multiple dated articles on May 11, 2026 report Cowboy Space raised $275 million in Series B financing at a $2 billion valuation to build rockets with orbital data-center upper stages, and a TechCrunch article says the company is standing up its own rocket program with a first launch expected before end-2028

Caveats: The reviewed sources contain no explicit negative event evidence; risk is inferred from execution complexity and long timeline, not from adverse events. Several supporting rows repeat the same May 11, 2026 financing story and are not independent confirmation. Some supporting article context is undated and should be treated cautiously for recency.

Thesis: Dawn Aerospace has the strongest opportunity evidence in this screen because a recent dated company article says it closed a $25 million Series B at a $195 million post-money valuation to accelerate global expansion of reusable space transportation. The funding is directly tied to rollout, commercial scaling in the US and Europe, and support for an expanding international customer base, which fits a 1 year+ horizon.

Why now: The key catalyst is recent and explicit: on June 16, 2026 the company announced the Series B close and said the proceeds will finance global rollout and scaling of commercial and operational teams in the US and Europe.

Caveats: Evidence comes from a company-published article, so it is not fully independent. No direct structured positive event row is provided beyond supporting article context.

Thesis: Eutelsat has a strong long-horizon opportunity case from the reviewed sources' membership rationale stating it is supervising a 264-satellite IRIS2 element and won a €350M French defense satellite contract with sovereign LEO capacity. That combines infrastructure scale with government-backed demand.

Why now: The reviewed sources' membership rationale cites current program/contract relevance through support articles 2026-04, and: but were not provided in the payload, limiting precise timing narration.

Caveats: The reviewed sources does not provide for the membership-support article IDs. Opportunity score is tempered by the absence of kept direct evidence in the ranking payload.

Thesis: No retained adverse evidence is provided, so no evidence-based risk thesis can be made.

Why now: No within the recent evidence window retained catalyst is available. The phase-2 rationale references, but no, timestamp, or retained summary is included.

Caveats: Support is provisional single-article context only. No retained direct evidence after recent evidence window. Payload mention does not prove company-level commercial traction.

Thesis: No material negative thesis is supportable from these reviewed sources because no direct negative evidence remains after recent evidence filtering.

Why now: There is no retained within the recent evidence window evidence for a current catalyst.

Caveats: Phase-2 rationale mentions a sponsored article and a partnership supporting Firefly's Blue Ghost lunar lander antennas, citing, but no or article summary is provided in these reviewed sources. Coverage debug shows 3 articles considered and 0 after recent evidence window. Sponsored-article context would be weaker than direct event/fact evidence even if fully provided.

Thesis: No material adverse evidence is available in the reviewed sources. Risk is limited to evidentiary uncertainty and boundary ambiguity around whether this specific activity is meaningful to ST Engineering's forward space thesis, not to a negative company event (: not provided in reviewed sources).

Why now: There is no usable dated direct evidence inside the recent evidence window; the reviewed sources explicitly shows articles after recent evidence window = 0 and evidence after recent evidence window = 0, so recency-based timing is unsupported.

Caveats: No direct evidence remained after the recent evidence filter. Representative articles are empty, so no is available in the reviewed sources. Membership rationale is weaker than company-specific event evidence.

Thesis: There is also no direct adverse evidence retained inside the 90-day recent evidence window, so no material risk thesis is supported beyond normal uncertainty from missing current evidence.

Why now: Why now is weak because the company had 10 articles considered, but zero article IDs and zero evidence remained after the 90-day recent evidence window cutoff of March 29, 2026; recency-based business-state judgment is therefore unavailable from these reviewed sources.

Caveats: No retained evidence after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Phase-2 membership rationale is not directional proof and cites support article IDs without, so it cannot be used as a fully cited factual thesis.

Thesis: No material adverse evidence is available within the reviewed sources' recent evidence window.

Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Starfighters Space.

Caveats: Phase-2 membership rationale references multiple article IDs, but the reviewed sources provide no article for citation.

Thesis: The reviewed sources have no retained 90-day adverse evidence, so there is not enough for a risk thesis.

Why now: No retained article IDs or evidence remain after recent evidence filtering, so there is no current evidence-based catalyst in the reviewed sources.

Caveats: Single-article historical context is not retained within the recent evidence window. Absence of negative evidence is not positive evidence. Scoring is conservative because the current reviewed sources is effectively ungrounded for direction.

Thesis: No material risk thesis is supportable because the reviewed sources retains no direct negative evidence within the recent evidence window.

Why now: Why now is weak: the reviewed sources indicates zero evidence after recent evidence window, so there is no retained current catalyst or current operating-state evidence for Starlab.

Caveats: Coverage after recent evidence window is empty for this company. Phase-2 membership rationale references, but no article summary or quoted evidence is included in the retained reviewed sources, so it cannot be used for factual claims here.

Thesis: The reviewed sources does not retain sufficient company-specific adverse evidence to support a risk thesis.

Why now: The membership rationale references article and says AISSat-4 is operated by StatSat, but no retained evidence or are present after recent evidence window, leaving recency and business impact uncertain.

Caveats: The only described support is a limited operational reference, not a clear catalyst. No direct dated evidence row is retained in the reviewed sources.

Thesis: No material adverse company-specific evidence is available in the retained recent evidence window. Risk score is kept slightly above zero only because coverage is thin and business status is unconfirmed in the reviewed sources.

Why now: There is no current catalyst supported by retained evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window, so recency and business-state changes cannot be assessed from these reviewed sources.

Caveats: No current evidence is provided for the cited support article in the reviewed sources. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Phase2 rationale is weaker than direct company-specific event evidence and should not be treated as strong proof.

Thesis: No material adverse evidence is shown. The low risk score reflects lack of documented negatives rather than evidence of resilience.

Why now: There is no identifiable catalyst because the reviewed sources provide only a passing mention and no direct event or fact evidence.

Caveats: No current evidence is provided for. Support level is provisional single-article context only. No evidence available after recent evidence window.

Thesis: No direct negative evidence is present. The main risk is that the company may be only tangentially relevant to the targeted space themes, making the opportunity thesis weak rather than making the company negatively exposed (: not provided in reviewed sources).

Why now: No inside-recent evidence window evidence are available, and the reviewed sources reports articles after recent evidence window = 0 and evidence after recent evidence window = 0, so there is no supported near-term or long-horizon timing catalyst beyond generic context.

Caveats: Single-article company universe but no representative article content or provided. Contract-award framing comes only through membership rationale, not direct evidence. No materiality, scale, or timing detail is available.

Thesis: No direct negative evidence is available in the reviewed sources, but absence of current retained evidence means business execution, financing, and mission timing remain uncertain.

Why now: Why now is weak because coverage data shows zero articles after recent evidence window and zero evidence after recent evidence window, so there is no current retained catalyst evidence in the last 90 days despite membership support referencing article

Caveats: Support exists only in the membership rationale, which cites article: but no or article summary is provided in the reviewed sources, so it cannot be cited as a factual claim under the the evidence standard. Evidence recent evidence review shows kept_rows 0 and coverage data shows evidence after recent evidence window 0.

Thesis: No retained within the recent evidence window direct negative evidence is available in the reviewed sources, so there is not enough support for a material risk thesis.

Why now: Coverage data reports zero article IDs after recent evidence window and zero evidence after recent evidence window, preventing a recency-based ranking call.

Caveats: Membership rationale references satellite communications and Lightspeed progress, but no article or retained evidence are supplied for ranking use. Public company status does not itself create a thesis without evidence.

Thesis: No material adverse evidence is present. The main limitation is evidentiary: TESAT's relevance may be real, but the reviewed sources does not provide company-specific directional evidence for either upside or downside (: not provided in reviewed sources).

Why now: No inside-recent evidence window direct evidence are available, so there is no supported timing argument.

Caveats: Relation evidence is context-only and cannot be propagated as direct contract evidence. No or representative article summary is provided. No company-specific materiality data is available.

Thesis: No material negative evidence is provided; risk remains low because the reviewed sources contain only context-level mention.

Why now: There is no within the recent evidence window direct company evidence. Membership rationale references, but no is provided and the support level is only provisional single-article context.

Caveats: Support is explicitly supporting article context, not direct company-specific event evidence. No retained evidence after recent evidence window. Relations/context-only mentions cannot be used as counterparty propagation evidence.

Thesis: No material adverse thesis is supported by the reviewed sources. The more relevant issue is uncertainty over evidence attribution from Thales Alenia Space to Thales parent.

Why now: There is no citable in-recent evidence window article summary or evidence row for Thales in these reviewed sources, and coverage data shows zero article ids after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase2 rationale references article ids: and: but no or summaries for them are included here. Parent/subsidiary propagation is explicitly uncertain in the reviewed sources rationale. No direct evidence were available after recent evidence window.

Thesis: No material adverse evidence is available. The main downside is uncertainty about business fit, commercialization path, and whether the government-support reference is meaningful at the company level.

Why now: The government RDI disbursal reference could matter on a 1 year+ horizon, but the reviewed sources lack timestamps, and direct evidence, limiting confidence in timing and materiality.

Caveats: No current evidence is provided for Government support mention is contextual and not enough alone to prove commercial traction. Zero evidence available after recent evidence window.

Thesis: No material adverse evidence is available within the recent evidence window.

Why now: There is no available within the recent evidence window evidence row after the March 29, 2026 cutoff; coverage data shows zero article IDs after recent evidence window and zero evidence after recent evidence window for Trishul Space.

Caveats: Phase-2 membership rationale references article: but the reviewed sources provide no for citation. Accelerator participation context is weaker than direct commercial, funding, or technical milestone evidence.

Thesis: No material adverse evidence is available. Risk remains low-scored due to lack of evidence rather than demonstrated business stability.

Why now: Why-now is weak because the cited raise and mission activity appear only in membership rationale, without scoreable dated article details in the current evidence set.

Caveats: Membership rationale cites, and, but the supporting articles are not available for direct use. Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. A positive thesis requires positive evidence; membership rationale alone only supports a modest watchlist bias.

Thesis: No material adverse evidence is available in the reviewed sources. Risk remains low-scored only because evidence is absent, not because the business is proven safe.

Why now: Why-now visibility is weak because the reviewed sources show zero evidence kept after recent evidence window for this company, so any claimed contract relevance lacks scoreable supporting detail in the current batch.

Caveats: Reviewed evidence cites: in membership rationale but does not provide article summary or available evidence, so it cannot be used as direct scoring evidence. Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Absence of negative evidence is not positive evidence.